The mission of the HIV Prevention Trials Network (HPTN) is to discover and develop interventions that can be used globally to prevent sexual and/or parenteral transmission of HIV. Our research encompasses the testing of novel biomedical and behavioral approaches. We seek HIV prevention strategies that are effective, safe, feasible, and sustainable, even in resource-limited settings. The incumbent HPTN has built field site research capacity in 16 developing countries. In the international HIVNET and the HPTN, we have recruited 31,250 HIV uninfected (principally) and infected persons into 38 trials (19,500 by the incumbent HPTN since 1999). Subjects are almost exclusively high risk, including adolescents and acutely infected persons. Focusing on resource-constrained countries in Africa, Asia, So. America, and E. Europe, as well as high incidence populations in the U.S., our highest impact trials have literally changed global public health practice. We are dividing the current HPTN agenda into three parts, with our perinatal group partnering to create IMPAACT, and our microbicide group spearheading the MTN. The new HPTN focus is fourfold: (1) antiretroviral therapy and co-infection therapy for viral load reduction and prevention of HIV transmission, (2) treatment of sexually transmitted infections (STI) to lower HIV transmission risk, (3) treatment of substance abuse and addiction, including injection drug use and stimulants (cocaine and methamphetamines) to reduce HIV transmission, and (4) behavioral risk reduction with biological endpoints. We use randomized controlled trials with HIV incidence endpoints in uninfected persons. For prevention research among acutely and chronically HIV-infected persons, we study incidence of non-HIV STIs, lowering of HIV viral load, and/or HIV incidence in sexual or needle-sharing partners. We propose to complete five ongoing HPTN trials and to transition an additional six ongoing HPTN trials to the IMPAACT and MTN networks, if funded. We present eight new trial concepts, five for prevention of HIV infection, one for detection and intervention among acutely infected persons (pre-seroconversion), and two focused on prevention among HIV-seropositive persons. Our risk populations include high risk heterosexuals, men who have sex with men, substance abusers, and, for selected trials, their sexual or needle-sharing partners. Our proposed affiliated Clinical Trials Units serve at-risk populations on five continents. The HPTN Leadership Group is diverse and includes experienced ethics experts and community leaders. HPTN governance is designed to develop and complete trials efficiently. We emphasize concepts of high potential public health impact, focusing on existing technologies that can be brought immediately into practice. Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI068619-07
Application #
8272708
Study Section
Special Emphasis Panel (ZAI1-TH-A (J2))
Program Officer
Gilbreath, Michael J
Project Start
2006-06-01
Project End
2013-12-31
Budget Start
2012-06-01
Budget End
2013-12-31
Support Year
7
Fiscal Year
2012
Total Cost
$16,330,898
Indirect Cost
$2,818,039
Name
Family Health International
Department
Type
DUNS #
067180786
City
Durham
State
NC
Country
United States
Zip Code
27713
Sivay, Mariya V; Hudelson, Sarah E; Wang, Jing et al. (2018) HIV-1 diversity among young women in rural South Africa: HPTN 068. PLoS One 13:e0198999
Salazar-Austin, N; Kulich, M; Chingono, A et al. (2018) Age-Related Differences in Socio-demographic and Behavioral Determinants of HIV Testing and Counseling in HPTN 043/NIMH Project Accept. AIDS Behav 22:569-579
Sabapathy, Kalpana; Hensen, Bernadette; Varsaneux, Olivia et al. (2018) The cascade of care following community-based detection of HIV in sub-Saharan Africa - A systematic review with 90-90-90 targets in sight. PLoS One 13:e0200737
Riddler, Sharon A; Zheng, Lu; Durand, Christine M et al. (2018) Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infect Dis 5:ofy242
Fogel, Jessica M; Sandfort, Theodorus; Zhang, Yinfeng et al. (2018) Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075. AIDS Behav :
Mitchell, Kate M; Dimitrov, Dobromir; Hughes, James P et al. (2018) In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? AIDS 32:809-818
Miller, William C; Hoffman, Irving F; Hanscom, Brett S et al. (2018) A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet 392:747-759
Rogers, Brooke G; Mendez, Noelle A; Mimiaga, Matthew J et al. (2018) ""I Wasn't in My Right Mind"": Qualitative Findings on the Impact of Alcohol on Condom Use in Patients Living with HIV/AIDS in Brazil, Thailand, and Zambia (HPTN 063). Int J Behav Med :
Zhang, Yinfeng; Sivay, Mariya V; Hudelson, Sarah E et al. (2018) Antiretroviral Drug Use and HIV Drug Resistance Among Young Women in Rural South Africa: HPTN 068. J Acquir Immune Defic Syndr 79:315-322
Shava, Emily; Lipira, Lauren E; Beauchamp, Geetha G et al. (2018) Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058. J Acquir Immune Defic Syndr 78:300-307

Showing the most recent 10 out of 192 publications